Share-based Payment Arrangement, Expense of Talis Biomedical Corp from 31 Mar 2020 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Talis Biomedical Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Jun 2024.
  • Talis Biomedical Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2024 was $791,000, a 26% decline year-over-year.
  • Talis Biomedical Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2024 was $3,484,000, a 28% decline year-over-year.
  • Talis Biomedical Corp annual Share-based Payment Arrangement, Expense for 2023 was $4,351,000, a 19% decline from 2022.
  • Talis Biomedical Corp annual Share-based Payment Arrangement, Expense for 2022 was $5,368,000, a 42% decline from 2021.
  • Talis Biomedical Corp annual Share-based Payment Arrangement, Expense for 2021 was $9,207,000, a 150% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Talis Biomedical Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $3,484,000 $791,000 -$285,000 -26% 01 Apr 2024 30 Jun 2024 10-Q 19 Aug 2024 2024 Q2
Q1 2024 $3,769,000 $601,000 -$582,000 -49% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $4,351,000 $1,020,000 -$262,000 -20% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2024 2023 FY
Q3 2023 $4,613,000 $1,072,000 -$224,000 -17% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $4,837,000 $1,076,000 -$169,000 -14% 01 Apr 2023 30 Jun 2023 10-Q 19 Aug 2024 2024 Q2
Q1 2023 $5,006,000 $1,183,000 -$362,000 -23% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $5,368,000 $1,282,000 -$1,886,000 -60% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $7,254,000 $1,296,000 -$1,180,000 -48% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $8,434,000 $1,245,000 -$546,000 -30% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $8,980,000 $1,545,000 -$227,000 -13% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $9,207,000 $3,168,000 +$1,604,000 +103% 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $7,603,000 $2,476,000 +$1,445,000 +140% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $6,158,000 $1,791,000 +$1,384,000 +340% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $4,774,000 $1,772,000 +$1,091,000 +160% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $3,683,000 $1,564,000 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $1,031,000 01 Jul 2020 30 Sep 2020 10-Q 16 Nov 2021 2021 Q3
Q2 2020 $407,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $681,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

Talis Biomedical Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $4,351,000 -$1,017,000 -19% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2024 2023 FY
2022 $5,368,000 -$3,839,000 -42% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $9,207,000 +$5,524,000 +150% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $3,683,000 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.